Eli founded Singular Genomics in 2016 and serves as the Chief Scientific Officer, leading both Science and Engineering R&D. Eli is passionate about advancing medicine through scientific discovery and engineering innovation. He has a broad range of expertise in physics, biology and engineering. Eli’s experience includes over 20 years of building and leading multi-disciplinary R&D teams in the biotech field. Prior to Singular Genomics, Eli served as the CTO at Meso Scale Diagnostics where he led the design and development of a market-leading multiplexed immunoassay technology, from early concepts to successful products. These instruments and assays are used for analyzing protein biomarkers in thousands of laboratories ranging from basic research to translational medicine, and have been used in over 1,500 publications. Eli’s an actively engaged technical leader and an inventor with over 60 issued US patents. Eli received a Ph.D. in Applied Physics from Harvard University and BAs in Physics and Mechanical Engineering from the University of California, Berkeley.
Advancing Speed, Versatility and Accuracy in NGS
Next Generation Sequencing (NGS) is a foundational technology for biological research and clinical diagnostics. We present Singular Genomics’ latest advances in accelerating the time to results, reducing sample batching constraints, and increasing the accuracy of DNA sequencing.
Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.